Cerus (NASDAQ:CERS – Get Free Report) is scheduled to announce its earnings results after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Cerus (NASDAQ:CERS – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. The company had revenue of $45.08 million during the quarter, compared to analyst estimates of $42.50 million. During the same quarter last year, the business posted ($0.07) earnings per share. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cerus Trading Up 3.0 %
Shares of CERS stock opened at $1.72 on Tuesday. The company has a market cap of $318.01 million, a PE ratio of -10.12 and a beta of 1.18. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.51 and a quick ratio of 1.83. The stock’s 50 day simple moving average is $1.92 and its two-hundred day simple moving average is $1.92. Cerus has a 1 year low of $1.25 and a 1 year high of $2.59.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on CERS
Insider Buying and Selling at Cerus
In related news, CFO Kevin Dennis Green sold 28,385 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company’s stock, valued at approximately $1,286,995.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Richard J. Benjamin sold 21,605 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $2.50, for a total value of $54,012.50. Following the transaction, the insider now directly owns 438,007 shares in the company, valued at approximately $1,095,017.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Kevin Dennis Green sold 28,385 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the transaction, the chief financial officer now directly owns 590,365 shares in the company, valued at $1,286,995.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
Cerus Company Profile
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Recommended Stories
- Five stocks we like better than Cerus
- 3 Fintech Stocks With Good 2021 Prospects
- Seagate: 4 Reasons to Buy-the-Dip on the Sell-the-News Reaction
- Options Trading – Understanding Strike Price
- Insiders Are Buying High-Yielding Delek Logistics Partners
- How to Choose Top Rated Stocks
- Cameco Is the Leading Play on Nuclear Power, And It Pays to Own
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.